RECRUITING

Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis

Talk to us

Conditions

Atopic DermatitisDermatitisEczemaModerate to severe

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This trial is designed to evaluate multiple compounds in participants with moderate to severe atopic dermatitis (AD).

Official Title

A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase II Platform Study to Assess the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis

Quick Facts

Study Start:2025-05-16
Study Completion:2028-11-27
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06947993

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 100 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. Age 18 years or older
  2. Willing and able to provide informed consent
  3. Able to understand and follow study procedures
  4. Stable medical condition
  1. Pregnancy or breastfeeding
  2. Severe psychiatric disorders
  3. Active substance abuse
  4. Unstable medical conditions
  5. Inability to comply with study requirements

Contacts and Locations

Study Contact

Novartis Pharmaceuticals
CONTACT
1-888-669-6682
novartis.email@novartis.com
Novartis Pharmaceuticals
CONTACT
+41613241111

Study Locations (Sites)

Novartis Investigative Site
Birmingham, Alabama, 35244
United States
Novartis Investigative Site
Los Angeles, California, 90056
United States
Novartis Investigative Site
Miami, Florida, 33144
United States
Novartis Investigative Site
Atlanta, Georgia, 30342
United States
Novartis Investigative Site
Macon, Georgia, 31217
United States
Novartis Investigative Site
Brighton, Massachusetts, 02135
United States
Novartis Investigative Site
Troy, Michigan, 48084
United States
Novartis Investigative Site
Saint Joseph, Missouri, 64506
United States
Novartis Investigative Site
Arlington, Texas, 76011
United States
Novartis Investigative Site
Cypress, Texas, 77433
United States
Novartis Investigative Site
San Antonio, Texas, 78218
United States

Collaborators and Investigators

Sponsor: Novartis Pharmaceuticals

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-05-16
Study Completion Date2028-11-27

Study Record Updates

Study Start Date2025-05-16
Study Completion Date2028-11-27

Terms related to this study

Keywords Provided by Researchers

  • Atopic dermatitis
  • Dermatitis
  • Eczema
  • Moderate to severe

Additional Relevant MeSH Terms

  • Atopic Dermatitis